Morphic Therapeutic announced the initiation of MORF-057-201, the EMERALD-1 study, a Phase IIa trial of MORF-057 in patients with moderate to severe ulcerative colitis.
[Morphic Therapeutic]
Sorry, but the selected Zotpress account can't be found.
